Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Neoadjuvant nivolumab for resectable lung cancer

Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

Neoadjuvant nivolumab for resectable lung cancer ( Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA )

Developing off-the-shelf CAR T cells with stem cell libraries

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Developing off-the-shelf CAR T cells with stem cell libraries ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )

Biomarkers of pembrolizumab response in head and neck cancer

Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Biomarkers of pembrolizumab response in head and neck cancer ( Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA )

Phase I taselisib results and a cell-free DNA assay

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )

Safety indications in mouse models treated with full doses of MEK inhibitors...

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York...

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

More from ecancer